Nuformix plc (LON:NFX – Get Free Report)’s stock price traded up 9.2% during trading on Thursday . The company traded as high as GBX 0.20 and last traded at GBX 0.20. 4,340,332 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 37,526,156 shares. The stock had previously closed at GBX 0.19.
Nuformix Price Performance
The business has a 50-day simple moving average of GBX 0.18 and a 200-day simple moving average of GBX 0.22. The firm has a market capitalization of £5.27 million, a PE ratio of -6.89 and a beta of 1.55.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
